Aligos Therapeutics, Inc.
Q2 2021 13F Holders
Symbol
ALGS
CUSIP
01626L105
Type
Equity
Class
COM
Num filings
58
Total reported value, excl. options
$550 M
Compare 2021 Q2 to
2024 Q4
2024 Q2
2024 Q1
2023 Q4
2023 Q3
2023 Q2
2023 Q1
2022 Q4
2022 Q3
2022 Q2
2022 Q1
2021 Q4
2021 Q3
2021 Q1
2020 Q4
Manager
Report Date
Value ($000)
Shares
Option Type